Pulmonary delivery of human protein C and factor IX

Advances in Experimental Medicine and Biology

Volumn 411, Issue , 1997, Pages 429-435

  Gupta, Shalabh ^a   Moussy, Francis ^a   Dalby, Richard N ^b   Miekka, Shirley I ^c   Bruley, Duane F ^a  

^a University of Marylandw Baltimore County   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; PROTEIN C;

AEROSOL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG STABILITY; NEBULIZATION; PRIORITY JOURNAL; PROTEIN STABILITY; SHEAR STRESS;

EID: 0030739653     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5865-1_55     Document Type: Article

References (6)

1. Vincent H. Lee: Changing needs in drug delivery in the era of peptide and protein drugs. Peptide and Protein Drug Delivery. Advances in Parenteral Sciences/4. (1991) 1-57.
2. Peter R. Byron: Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung. Advanced Drug Delivery Reviews, 5 (1990) 107-132.
3. Ulla Hedner, Earl W. Davie: Introduction to Hemostasis and vitamin K dependent coagulation factors., Blood and blood forming tissue. 2107-2133
4. J. Bryan Smith: Drugs affecting coagulation, fibrinolysis, and platelet aggregation. Human Pharmacology, Molecular to Clinical. (1995) 21.
5. Ralph W. Niven: Delivery of Biotherapeutics by Inhalation aerosols. Ralph W. Niven. J. Pharmaceutical Technology (July 1993) 72.
6. Peter R. Byron :Pulmonary targeting with aerosols. J. Pharmaceutical Technology (43). May 1987.